[go: up one dir, main page]

AR054808A1 - Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes - Google Patents

Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes

Info

Publication number
AR054808A1
AR054808A1 ARP060102810A ARP060102810A AR054808A1 AR 054808 A1 AR054808 A1 AR 054808A1 AR P060102810 A ARP060102810 A AR P060102810A AR P060102810 A ARP060102810 A AR P060102810A AR 054808 A1 AR054808 A1 AR 054808A1
Authority
AR
Argentina
Prior art keywords
derivative
compositions
iron oxide
coverage
acceptable
Prior art date
Application number
ARP060102810A
Other languages
English (en)
Inventor
Andreas Briel
Bernhard Gleich
Jurgen Weizenecker
Martin Rohrer
Hanns-Joachim Weinmann
Hubertus Pietsch
Ruediger Lawaczeck
Matthias Rother
Jens Thomsen
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR054808A1 publication Critical patent/AR054808A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/418—Evaluating particular organs or parts of the immune or lymphatic systems lymph vessels, ducts or nodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/0515—Magnetic particle imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/415—Evaluating particular organs or parts of the immune or lymphatic systems the glands, e.g. tonsils, adenoids or thymus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/416—Evaluating particular organs or parts of the immune or lymphatic systems the spleen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1836—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Iron (AREA)

Abstract

Complejos que contienen partículas magnéticas de oxido de hierro policristalino en una cobertura aceptable para uso farmacéutico, y al uso de dichas composiciones en el diagnostico por imágenes con partículas magnéticas (MPI). Se prefiere en particular el uso de dichas composiciones en exámenes del tracto gastrointestinal, del sistema vascular cardíaco y componentes craneanos, en el diagnostico de arteriosclerosis, infartos y tumores y metástasis, por ejemplo del sistema linfático. Reivindicacion 1: Una partícula caracterizada porque comprende, dentro de una cobertura aceptable para uso farmacéutico, un nucleo de oxido de hierro magnético policristalino con un diámetro entre 20 nm y 1 micron. Reivindicacion 3: Una partícula de acuerdo con la reivindicacion 1 o 2, caracterizada porque la cobertura aceptable para uso farmacéutico comprende un polímero o copolímero sintético, un almidon o un derivado del mismo, un dextrano o un derivado del mismo, un ciclodextrano o un derivado del mismo, un ácido graso, un polisacárido, una lecitina o un mono-, di- o triglicérido o un derivado del mismo o mezclas de los mismos. Reivindicacion 11:Un método para producir partículas que comprende, dentro de una cobertura aceptable para uso farmacéutico, un nucleo de oxido de hierro magnético policristalino con un diámetro entre 20 nm y 1micron, caracterizado porque dicho método comprende los siguientes pasos: ( i ) mezclar una solucion acuosa mixta de sales de hierro, que contiene una sal de hierro (II) y una sal de hierro (III), con una solucion alcalina acuosa en presencia de un polímero o copolímero sintético, un almidon o un derivado del mismo, un dextrano o un derivado del mismo, un ciclodextrano o un derivado del mismo, un ácido graso, un polisacárido, una lecitina o un mono-, di- o triglicérido o un derivado del mismo o mezclas de los mismos, hasta que se forma una suspension coloidal de las partículas, /ii) hacer pasar la solucion que contiene la partícula a través de un gradiente de campo magnético, (iii) quitar el gradiente de campo magnético, (iv) y recuperar las partículas retenidas en el gradiente de campo.
ARP060102810A 2005-06-29 2006-06-29 Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes AR054808A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05014058A EP1738773A1 (de) 2005-06-29 2005-06-29 Magnetische Eisenoxidpartikel enthaltende Zusammensetzung und deren Vervendung in bildgebenden Verfahren

Publications (1)

Publication Number Publication Date
AR054808A1 true AR054808A1 (es) 2007-07-18

Family

ID=35432430

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102810A AR054808A1 (es) 2005-06-29 2006-06-29 Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes

Country Status (14)

Country Link
US (2) US20070014730A1 (es)
EP (2) EP1738773A1 (es)
JP (1) JP5366543B2 (es)
CN (1) CN101365495B (es)
AR (1) AR054808A1 (es)
BR (1) BRPI0611756A2 (es)
DO (1) DOP2006000154A (es)
GT (1) GT200600288A (es)
PA (1) PA8684201A1 (es)
PE (1) PE20070345A1 (es)
RU (1) RU2420319C2 (es)
TW (1) TW200800275A (es)
UY (1) UY29643A1 (es)
WO (1) WO2007000351A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1738774A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzungen und deren Verwendung in bildgebenden Verfahren
CN104042214A (zh) 2007-01-24 2014-09-17 皇家飞利浦电子股份有限公司 用于影响和/或探测作用区域中的磁性粒子的方法、磁性粒子以及磁性粒子的使用
WO2009122330A2 (en) 2008-04-03 2009-10-08 Koninklijke Philips Electronics N. V. Biocompatible products for magnetic particle imaging
US20110316526A1 (en) 2009-03-09 2011-12-29 Koninklijke Philips Electronics N.V. Arrangement and method for measuring a magnetic material in a region of action
KR101085824B1 (ko) * 2009-03-11 2011-11-23 한국유나이티드제약 주식회사 생체적합성 고분자를 이용한 다기능성 조영제 및 이의 제조방법
US9451900B2 (en) 2009-05-08 2016-09-27 Koninklijke Philips N.V. Arrangement and method for heating of a magnetic material
WO2011001351A1 (en) * 2009-07-01 2011-01-06 Koninklijke Philips Electronics N. V. Stimuli-responsive carriers for mpi-guided drug delivery
CN102481118B (zh) * 2009-09-14 2015-08-19 皇家飞利浦电子股份有限公司 用于移动和激活活性剂的设备
US9259492B2 (en) 2010-06-21 2016-02-16 University Of Washington Through Its Center For Commercialization Tuned multifunctional magnetic nanoparticles for biomedicine
US9555136B2 (en) 2010-06-21 2017-01-31 University Of Washington Through Its Center For Commercialization Coated magnetic nanoparticles
WO2012007871A1 (en) 2010-07-13 2012-01-19 Koninklijke Philips Electronics N.V. System and method for generating a system function for use in the reconstruction of images
RU2497546C1 (ru) * 2012-04-23 2013-11-10 Общество с ограниченной ответственностью "Ланда Фармасьютикалз" Магнитно-резонансное и рентгеновское контрастное средство и способ его получения
CN103316361B (zh) * 2013-07-08 2015-04-01 武汉百仕康生物科技有限公司 一种稳定的纳米级超顺磁氧化铁溶液及其制备方法和应用
CN103704232B (zh) * 2013-11-01 2016-01-06 北京科技大学 纳米农药羧甲基-β-环糊精-Fe3O4磁性纳米-敌草隆的制备方法
ES2800524T3 (es) * 2013-12-13 2020-12-30 Mercury Asset Man Co Ltd Composición de imagen de cartílago articular
US10898581B2 (en) * 2014-01-16 2021-01-26 The Brigham And Women's Hospital, Inc. Targeted delivery of immunoregulatory drugs
JP2019151552A (ja) * 2016-07-12 2019-09-12 名糖産業株式会社 磁性粒子
KR102243351B1 (ko) * 2017-01-12 2021-04-21 가부시키가이샤 무라타 세이사쿠쇼 자성체 입자, 압분 자심, 및 코일 부품
KR102692719B1 (ko) * 2018-08-09 2024-08-08 (주)아모레퍼시픽 미세먼지 제거용 다공성 복합분체 및 이의 제조방법
CN111298140B (zh) * 2020-03-24 2022-04-19 中国科学院苏州纳米技术与纳米仿生研究所 还原响应的t1/t2切换型mri造影剂、其制备方法及应用
WO2022244093A1 (ja) * 2021-05-18 2022-11-24 三菱電機株式会社 生体情報検出装置および生体情報検出方法
CN115125537B (zh) * 2022-08-05 2023-04-11 四川轻化工大学 一种脱除聚晶金刚石复合片中钴的方法
CN119001121A (zh) * 2024-10-23 2024-11-22 上海拜谱生物科技有限公司 Cmb磁珠试剂盒及其在半胱氨酸修饰蛋白组学分析中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102780A (en) * 1976-03-09 1978-07-25 S. G. Frantz Company, Inc. Method and apparatus for magnetic separation of particles in a fluid carrier
IL98744A0 (en) * 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
US5766572A (en) * 1992-08-05 1998-06-16 Meito Sangyo Kabushiki Kaisha Water-soluble carboxypolysaccharide-magnetic iron oxide complex having a small particle diameter
JPH08508721A (ja) * 1993-03-17 1996-09-17 シリカゲル ゲス．エム．ビー．エイチ 超常磁性粒子、その製法及びその用途
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
AU687093B2 (en) * 1994-09-27 1998-02-19 Nycomed Imaging As Contrast agent
DE19624426A1 (de) * 1996-06-19 1998-01-02 Christian Bergemann Magnetische Flüssigkeiten für den Transport von diagnostisch oder therapeutisch wirksamen Substanzen
ES2171985T3 (es) * 1996-08-05 2002-09-16 Schering Ag Procedimiento para la preparacion de agentes de contraste destinados a la tomografia por resonancia magnetica.
BR9907852A (pt) * 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
GB9921579D0 (es) * 1999-09-13 1999-11-17 Nycomed Imaging As
AU4305101A (en) * 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
DE10151778A1 (de) * 2001-10-19 2003-05-08 Philips Corp Intellectual Pty Verfahren zur Ermittlung der räumlichen Verteilung magnetischer Partikel
JP4583370B2 (ja) * 2003-04-15 2010-11-17 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 検査領域内の磁性粒子の分布を空間分解して特定する方法
EP1615558B1 (en) * 2003-04-15 2012-02-22 Philips Intellectual Property & Standards GmbH Method for the spatially resolved determination of physical, chemical and biological properties or state variables
JP4890242B2 (ja) * 2003-04-15 2012-03-07 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 検査エリアにおける状態変数の空間分解を決定する装置及び方法
US20070258888A1 (en) * 2003-11-17 2007-11-08 Claus Feldmann Contrast Agent for Medical Imaging Techniques and Usage Thereof
EP1738774A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzungen und deren Verwendung in bildgebenden Verfahren

Also Published As

Publication number Publication date
DOP2006000154A (es) 2008-05-15
BRPI0611756A2 (pt) 2012-04-17
RU2008103203A (ru) 2009-08-10
GT200600288A (es) 2007-03-14
EP1898960A1 (en) 2008-03-19
EP1738773A1 (de) 2007-01-03
CN101365495A (zh) 2009-02-11
US20070036729A1 (en) 2007-02-15
RU2420319C2 (ru) 2011-06-10
JP2008544968A (ja) 2008-12-11
US20070014730A1 (en) 2007-01-18
TW200800275A (en) 2008-01-01
PA8684201A1 (es) 2007-01-17
UY29643A1 (es) 2007-01-31
PE20070345A1 (es) 2007-04-20
WO2007000351A1 (en) 2007-01-04
CN101365495B (zh) 2013-09-04
JP5366543B2 (ja) 2013-12-11

Similar Documents

Publication Publication Date Title
AR054808A1 (es) Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes
Abdukayum et al. Gadolinium complexes functionalized persistent luminescent nanoparticles as a multimodal probe for near-infrared luminescence and magnetic resonance imaging in vivo
Tran et al. Multifunctional iron oxide magnetic nanoparticles for biomedical applications: a review
Cheng et al. Polydopamine-coated manganese carbonate nanoparticles for amplified magnetic resonance imaging-guided photothermal therapy
US20220404349A1 (en) Methods and uses for remotely triggered protease activity measurements
Colombo et al. Biological applications of magnetic nanoparticles
Xu et al. Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood
Di Corato et al. Multifunctional nanobeads based on quantum dots and magnetic nanoparticles: synthesis and cancer cell targeting and sorting
Saladino et al. Optical and X-ray fluorescent nanoparticles for dual mode bioimaging
Sun et al. Effect of crystal shape and aggregation of calcium oxalate monohydrate on cellular toxicity in renal epithelial cells
US20110021745A1 (en) Ultra-small chitosan nanoparticles useful as bioimaging agents and methods of making same
Yin et al. Folic acid-conjugated organically modified silica nanoparticles for enhanced targeted delivery in cancer cells and tumor in vivo
CN103845741B (zh) 基于介孔二氧化硅双模式荧光/磁共振成像造影剂及制备
CN105462580B (zh) 一种荧光靶向的锌掺杂四氧化三铁纳米颗粒及制备
Cai et al. Self-assembled hybrid nanocomposites for multimodal imaging-guided photothermal therapy of lymph node metastasis
Addisu et al. Mixed lanthanide oxide nanoparticles coated with alginate-polydopamine as multifunctional nanovehicles for dual modality: Targeted imaging and chemotherapy
Magnabosco et al. Effect of surface chemistry on incorporation of nanoparticles within calcite single crystals
Lee et al. Hybrid composite of silver nanoparticle–porous silicon microparticles as an image-guided localization agent for computed tomography scan of the lungs
Zhou et al. Mitochondria-localized self-reporting small-molecule-decorated theranostic agents for cancer-organelle transporting and imaging
Wang et al. All-in-One strategy for downstream molecular profiling of tumor-derived exosomes
Devkota et al. Nanoparticle Contrast Agents for Photon‐Counting Computed Tomography: Recent Developments and Future Opportunities
AU2017203920B2 (en) Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
Yang et al. MIL-53 (Al)–oil/water emulsion composite as an adjuvant promotes immune responses to an inactivated pseudorabies virus vaccine in mice and pigs
CN110079311B (zh) 一种纳米荧光探针的制备方法及其在检测bv2细胞活化状态中的应用
Liu et al. Biocompatible KMnF3 nanoparticular contrast agent with proper plasma retention time for in vivo magnetic resonance imaging

Legal Events

Date Code Title Description
FA Abandonment or withdrawal